Literature DB >> 9332509

Prevalence of human immunodeficiency virus infection, mortality rate, and serogroup distribution among patients with pneumococcal bacteremia at Denver General Hospital, 1984-1994.

J R Hibbs1, J M Douglas, F N Judson, W L McGill, C A Rietmeijer, E N Janoff.   

Abstract

Pandemics of human immunodeficiency virus (HIV) type 1 infection and penicillin resistance highlight the urgency of preventing invasive pneumococcal disease with vaccination. We characterized pneumococcal serogroup distribution and the mortality rate among 460 patients with pneumococcal bacteremia from 1984 through 1994 at Denver General Hospital and the prevalence of HIV infection in patients for whom pneumococcal bacteremia was diagnosed from 1989 to 1994. Vaccine-related serogroups accounted for 426 isolates (92.6%), including 48 (92.3%) of 52 isolates from HIV-infected patients. Mortality among patients 15 years of age or older was higher during 1984-1988 (18[12.9%] of 140) than during 1989-1994 (10 [5.2%] of 191: rate ratio, 2.5; 95% confidence interval, 1.2-5.2). Of patients 15-59 years of age from 1989 to 1994, 44 (39.6%) of 111 men and three (7.3%) of 41 women were HIV-infected. Four (8.5%) of 47 HIV-infected patients and four (3.8%) of 105 other patients in this group died (age-weighted rate ratio, 1.8; 95% confidence interval, 0.5-6.2). We recommend routine screening of young adults with pneumococcal bacteremia for HIV infection and immunization of HIV-infected patients with pneumococcal vaccine (which includes most serogroups of infecting strains).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9332509     DOI: 10.1086/514538

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  8 in total

1.  Nosocomial or Healthcare Facility-Related Pneumonia in Adults.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

2.  Macrolide resistance in Streptococcus pneumoniae: Fallacy or fact?

Authors:  Jm Conly; Bl Johnston
Journal:  Can J Infect Dis       Date:  2002-01

3.  A randomized clinical trial comparing revaccination with pneumococcal conjugate vaccine to polysaccharide vaccine among HIV-infected adults.

Authors:  Nancy F Crum-Cianflone; Katherine Huppler Hullsiek; Mollie Roediger; Anuradha Ganesan; Sugat Patel; Michael L Landrum; Amy Weintrob; Brian K Agan; Sheila Medina; Jeremy Rahkola; Braden R Hale; Edward N Janoff
Journal:  J Infect Dis       Date:  2010-10-01       Impact factor: 5.226

Review 4.  Bloodstream infections in HIV-infected patients.

Authors:  Lucia Taramasso; Paola Tatarelli; Antonio Di Biagio
Journal:  Virulence       Date:  2016-04-02       Impact factor: 5.882

5.  Vaccination in HIV-infected Patients.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.663

6.  HIV Infection and the Epidemiology of Invasive Pneumococcal Disease (IPD) in South African Adults and Older Children Prior to the Introduction of a Pneumococcal Conjugate Vaccine (PCV).

Authors:  Susan Meiring; Cheryl Cohen; Vanessa Quan; Linda de Gouveia; Charles Feldman; Alan Karstaedt; Keith P Klugman; Shabir A Madhi; Helene Rabie; Charlotte Sriruttan; Anne von Gottberg
Journal:  PLoS One       Date:  2016-02-10       Impact factor: 3.240

7.  Pneumococcal disease in HIV-infected Malawian adults: acute mortality and long-term survival.

Authors:  Stephen B Gordon; Mas Chaponda; Amanda L Walsh; Christopher J M Whitty; Melita A Gordon; C Edward Machili; Charles F Gilks; Martin J Boeree; Sam Kampondeni; Robert C Read; Malcolm E Molyneux
Journal:  AIDS       Date:  2002-07-05       Impact factor: 4.177

8.  Patient outcome in adults with pneumococcal meningitis or bacteraemia admitted to QECH.

Authors:  Stephen B Gordon
Journal:  Malawi Med J       Date:  2003-06       Impact factor: 0.875

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.